CCN1 and pancreatic ductal adenocarcinoma: Additional recent studies on CYR61-driven development of cell motility in pancreatic ductal adenocarcinoma and in gastric epithelial cells [38], [39] indicate that CYR61 is one of the key molecules for EMT that could confer metastatic ability and cell motility to a primary tumor.